Immune reconstitution inflammatory syndrome (IRIS) is a violent inflammatory response in a patient previously immunosuppressed that discontinued this status and develops a paradoxical clinical deterioration, not explainable with drug-toxicity or opportunistic infection. We describe the case of a 59-year-old non-smoking man, treated for arthropathic psoriasis with adalimumab for 16 months who developed severe IRIS and pulmonary tuberculosis. The reintroduction of the TNF-blocker agent was effective.

An adalimumab-induced late-onset immune reconstitution inflammatory syndrome treated with adalimumab

Marco Confalonieri
Conceptualization
;
Nicola Di Meo;Giovanni Damiani
;
Giusto Trevisan
2018-01-01

Abstract

Immune reconstitution inflammatory syndrome (IRIS) is a violent inflammatory response in a patient previously immunosuppressed that discontinued this status and develops a paradoxical clinical deterioration, not explainable with drug-toxicity or opportunistic infection. We describe the case of a 59-year-old non-smoking man, treated for arthropathic psoriasis with adalimumab for 16 months who developed severe IRIS and pulmonary tuberculosis. The reintroduction of the TNF-blocker agent was effective.
File in questo prodotto:
File Dimensione Formato  
An adalimumab-induced late-onset immune reconstitution inflammatory syndrome treated with adalimumab 2018.pdf

Accesso chiuso

Descrizione: articolo principale
Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 462.36 kB
Formato Adobe PDF
462.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2920498
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact